A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration

To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for anti–vascular endothelial growth factor therapy over a 12-week period in patients with neovascular age-related macular degeneration. A phase 2 multicent...

Full description

Bibliographic Details

Published in:	American journal of ophthalmology Vol. 239; pp. 180 - 189
Main Authors:	Poor, Stephen H., Weissgerber, Georges, Adams, Christopher M., Bhatt, Harit, Browning, David J., Chastain, James, Ciulla, Thomas A., Ferriere, Michael, Gedif, Kinfemichael, Glazer, Louis C., Joondeph, Brian C., Normand, Guillaume, Sheth, Veeral, Watters, Christie, Grosskreutz, Cynthia L.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.07.2022 Elsevier Limited
Subjects:	Antibodies Clinical trials Diabetic retinopathy Drug dosages Immunoglobulins Kinases Laboratories Macular degeneration Monoclonal antibodies Patients Vascular endothelial growth factor United States > US
ISSN:	0002-9394, 1879-1891, 1879-1891
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!